Vincerx Pharma Inc (VINC)

Vincerx Pharma Inc. is a clinical-stage biopharmaceutical company listed on OTC Markets as common stock under the ticker VINC. The company focuses on developing cancer therapies aimed at unmet medical needs, with a pipeline centered on its VersAptx bioconjugation platform. This platform combines targeting, linker, and payload technologies used in antibody-drug conjugates and small molecule drug conjugates, and it also includes CellTrapper technology designed to reduce payload cell permeability. Its clinical programs include VIP943, an antibody-drug conjugate in a Phase 1 dose-escalation study for relapsed or refractory acute myeloid leukemia, higher-risk myelodysplastic syndromes, and B-cell acute lymphoblastic leukemia, as well as VIP236, an SMDC being studied in Phase 1 for advanced or metastatic solid tumors. The company is also advancing VIP924 in preclinical research for B-cell malignancies and has a collaboration with the National Institutes of Health on enitociclib, a selective CDK9 inhibitor. Founded in 2019 and headquartered in San Mateo, California, the company adopted the Vincerx Pharma name in January 2021.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.